NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Bicycle Therapeutics plc (BCYC) Stock Analysis

Bicycle Therapeutics plc (BCYC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BCYC

$4.30

+$0.06 (+1.42%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCYC with… →

BCYC Key Statistics

As of Sep 4, 2026
Trading
Open
$4.20
Previous Close
$4.24
Day's Range
4.15–4.31
52-Week Range
3.75–9.16
Volume
157.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.54
Valuation
Market Cap
$300.97M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.92
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.73
Financials (FY)
Revenue (FY)
$72.59M+105.77%
Net Income (FY)
−$218.96M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
50.55M
1-Year Return
−38.31%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
422.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BCYC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.27%
2025−49.43%
2024−22.57%
2023−38.92%
2022−51.37%
2021+239.11%
2020+90.35%
2019 (partial year)−21.42%

As of September 4, 2026.

BCYC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$72.59M−$218.96M−301.7%
2024$35.28M−$169.03M−479.2%
2023$26.98M−$180.66M−669.7%
2022$14.46M−$112.72M−779.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$72.59M—−$247.72M−$218.96M−301.7%
2024$35.28M—−$209.15M−$169.03M−479.2%
2023$26.98M—−$189.95M−$180.66M−669.7%
2022$14.46M—−$116.65M−$112.72M−779.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BCYC Valuation vs Biotechnology Median

Median of 656 stocks
MetricBCYCBiotechnology medianvs median
P/S ratio4.9215.260.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bicycle Therapeutics plc (BCYC) carries a market capitalisation of $300.97M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 288.

The most recent close on file for BCYC is $4.30, dated September 4, 2026. That is +$0.06 (+1.42%) against the previous close. Over the past 52 weeks the price has ranged from $3.75 to $9.16. The latest close sits 14.82% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $72.59M. That is +105.77% against the prior fiscal year, when revenue was $35.28M. The same year closed with a net loss of $218.96M. Profit margin runs at 0%. Trailing earnings per share are −2.73.

Across the 4 fiscal years on file, revenue moves from $14.46M in 2022 to $72.59M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 4.92 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −38.31%. Across 5 years the annualized return works out at −35.99%. Beta against the wider market is reported at 1.54. Daily returns over the trailing 7 years annualize to a volatility of 69.84%.

Growth & Income

No dividend is on file for BCYC.

Across the complete calendar years on file, 2021 returned +239.11% and 2022 returned −51.37%. Of the 6 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −39.27% year to date.

Peer Comparison

Bicycle Therapeutics plc (BCYC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bicycle Therapeutics plc BCYC $300.97M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Bicycle Therapeutics plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Visit website →